Dianthus Therapeutics (DNTH) vs Erasca (ERAS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Erasca (ERAS) has outperformed Dianthus Therapeutics (DNTH) over the past year, gaining 469.4% versus a gain of 144.6%. Over five years, ERAS leads with a -20.7% price change compared with -21.2% for DNTH. Erasca is the larger company by market cap ($5.02 billion vs $4.57 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | ERAS |
|---|---|---|
| Share price | $81.66 | $14.34 |
| Market cap | $4.57B | $5.02B |
| 1-day change | -3.79% | +1.56% |
| YTD return | +105.97% | +279.57% |
| 1-year return | +144.61% | +469.35% |
| 5-year return | -21.17% | -20.67% |
| EPS (TTM) | $-4.24 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | — |
| Revenue growth (YoY) | -67.35% | — |
| Net income (latest FY) | $-162.34M | $-124.55M |
| Operating margin | -8739.34% | — |
| Net margin | -7973.33% | — |
| 52-week high | $117.88 | $24.28 |
| 52-week low | $32.22 | $2.11 |
| Distance from 52-week high | -30.73% | -40.94% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +72.42% | +68.13% |
| Average volume | 821.22K | 4.28M |
| Shares outstanding | 55.93M | 349.76M |
| Employees | 92 | 103 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed DNTH by 324.7 percentage points over the past year.
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
DNTH vs ERAS FAQ
Which is bigger, Dianthus Therapeutics or Erasca?
Erasca (ERAS) is larger, with a market capitalization of $5.02B compared with $4.57B for Dianthus Therapeutics (DNTH).
Which stock has performed better over the past year, DNTH or ERAS?
ERAS returned +469.35% over the past 12 months, compared with +144.61% for DNTH (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and Erasca in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.